Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicityLenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
- Other Titles
- Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
- Authors
- Junshik Hong; Yoo Jin Lee; Sung Hwa Bae; Jun Ho Yi; Sungwoo Park; Myung Hee Chang; Young Hoon Park; Shin Young Hyun; Joo Seop Chung; Ji Eun Jang; Joo Young Jung; So Yeon Jeon; Seo-Young Song; Hawk Kim; Dae Sik Kim; Sung Hyun Kim; Min Kyoung Kim; Sang Hoon Han; Seonyang Park; Yoo-Jin Kim; Je-Hwan Lee
- Issue Date
- Jun-2021
- Publisher
- 대한혈액학회
- Keywords
- 5q deletion syndrome; Myelodysplastic syndrome; Lenalidomide; Anemia
- Citation
- Blood Research, v.56, no.2, pp.102 - 108
- Journal Title
- Blood Research
- Volume
- 56
- Number
- 2
- Start Page
- 102
- End Page
- 108
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81767
- DOI
- 10.5045/br.2021.2021086
- ISSN
- 2287-979X
- Abstract
- Background To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea.
Methods Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed.
Results A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades ≥3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%).
Conclusion Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81767)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.